Education Program
Biological therapies, Lymphomas, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Lymphoid Malignancies
Room 6CF
(San Diego Convention Center)
Description:
CD19 directed CAR-T cell therapy represents a breakthrough in cancer treatment achieving unprecedented success in relapsed/refractory B cell lymphomas. However, the economic burden related to manufacturing and logistics, adverse events such as cytokine release syndrome (CRS), neurotoxicity, infections and cytopenias underscores the importance of assessing prognostic and predictive tools for therapy success. Outcome of patients who progress after CAR-T cell therapy is poor in the current era and management remains unclear. BITE’s are recently approved off-the-shelf T cell engagers that have shown excellent efficacy and tolerability leading to regulatory approval in relapsed lymphomas. Thus, the ideal sequencing of T cell therapies in relapsed aggressive lymphomas necessitates a roadmap to further guide the contemporaneous management of lymphomas.
Chair:
Manali K. Kamdar, MD, MBBS, University of Colorado,
Disclosures:
Kamdar: AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene, Genentech, syncopation, caribou biosciences: Consultancy; Genentech, Celgene: Other: DMC; Novartis: Research Funding; SeaGen: Speakers Bureau.
CD19 directed CAR-T cell therapy represents a breakthrough in cancer treatment achieving unprecedented success in relapsed/refractory B cell lymphomas. However, the economic burden related to manufacturing and logistics, adverse events such as cytokine release syndrome (CRS), neurotoxicity, infections and cytopenias underscores the importance of assessing prognostic and predictive tools for therapy success. Outcome of patients who progress after CAR-T cell therapy is poor in the current era and management remains unclear. BITE’s are recently approved off-the-shelf T cell engagers that have shown excellent efficacy and tolerability leading to regulatory approval in relapsed lymphomas. Thus, the ideal sequencing of T cell therapies in relapsed aggressive lymphomas necessitates a roadmap to further guide the contemporaneous management of lymphomas.
Anna Maria Sureda Balari, MD, PhD
Clinical Hematology Department, Institut Català d'Oncologia-L'Hospitalet, IDIBALL, Universitat de Barcelona, Barcelona, Spain
Loretta J. Nastoupil, MD
Lymphoma/Myeloma Department, MD Anderson Cancer Center, Houston, TX; Department of Lymphoma and Myeloma, UT MD Anderson Cancer Center, Houston, TX
Manali K. Kamdar, MD, MBBS
University of Colorado,, Denver, CO
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.